This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Marc J. Siegel, MD; Henry J. Spiro, MD; Joel A. Miller, MD; Les I. Siegel, MD
Southfield, Mich

Arch Ophthalmol. 1991;109(11):1496-1497.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Orcolon is a high-molecular-weight viscoelastic agent (purified polyacrylamide polymer) manufactured by Optical Radiation Corp (Azusa, Calif) for use in intraocular procedures. Two multicenter clinical trials in patients undergoing cataract surgery performed as part of the Food and Drug Administration approval process failed to detect any pattern of intraocular toxic effects. Nonetheless, we recently evaluated two patients who suffered postoperative complications that we believe may be secondary to the use of this substance.

Report of Cases.

—On April 22, 1991, a total of 12 patients underwent uneventful cataract surgery performed by the same surgeon (H.J.S.) at the same surgical facility. All patients underwent the same preoperative, intraoperative, and postoperative regimen. Intraoperative medications used consisted of balanced salt solution (Alcon) with 0.5 mL of epinephrine, 50 mg/mL vancomycin hydrochloride, and 40 mg/mL gentamicin sulfate, 0.01% carbachol (Miostat), and Orcolon in the anterior chamber; balanced salt solution (Alcon), tobramycin . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?